Skip to main content
. 2016 May 11;29(3):282–296. doi: 10.20524/aog.2016.0041

Table 2.

European medicines agency-approved regimens for daclatasvir in patients with hepatitis C virus infection

graphic file with name AnnGastroenterol-29-282-g002.jpg